Image

Colombia Gastric Cancer Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Feb 2022
  • Country Level
  • 350 Pages
  • No of Tables: 12
  • No of Figures: 40

Colombia Gastric Cancer Drugs Market, By Type (Adenocarcinoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Lymphoma, and Others), Stage (Stage III, Stage II, Stage IV, Stage I, and Others), Treatment (Chemotherapy, Targeted Therapy, Immune Checkpoint Inhibitors, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Research & Academic Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) Industry Trends and Forecast to 2029

Market Analysis and Insights : Colombia Gastric Cancer Drugs Market

Colombia gastric cancer drugs market is expected to gain significant growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyzes that the market is growing with a CAGR of 8.5% in the forecast period of 2022 to 2029 and is expected to reach USD 47.73 million by 2029. Rising cases of gastrointestinal tumors, lymphoma and adenocarcinoma have increased the demand for medication and treatment, which is expected to drive the growth of the gastric cancer drugs market.

Gastric cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. The age, diet, and stomach disease can affect the risk of developing gastric cancer. Symptoms of gastric cancer include indigestion and stomach discomfort or pain. Stomach cancers tend to develop slowly over many years. Before a true cancer develops, pre-cancerous changes often occur in the inner lining (mucosa) of the stomach before the complete development of the cancer. These early changes rarely cause symptoms, so they often go undetected. Cancer’s development in different sections of the stomach can cause different symptoms and tend to have different outcomes. Its location can also affect treatment options.

Rising incidence of gastric cancers and increasing healthcare expenditure are expected to drive the growth of market across Colombia.

Colombia Gastric Cancer Drugs Market

Colombia Gastric Cancer Drugs Market Scope and Market Size

The Colombia gastric cancer drugs market is segmented on the basis of type, stage, treatment, route of administration, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of type, the market is segmented into adenocarcinoma, lymphoma, gastrointestinal stromal tumour, carcinoid tumour, and others. In 2022, the adenocarcinoma segment is expected to dominate the Colombia gastric cancer treatment market due to excessive research and development in producing drugs for this market.
  • On the basis of stage, the market is segmented into stage I, stage II, stage III, stage IV, and others. In 2022, the stage III segment is expected to dominate the Colombia gastric cancer drugs market as this stage spreads very quickly and delayed diagnosis of gastric cancer leads the stages of cancer which is the reason behind stage III dominance.
  • On the basis of treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy, and others. In 2022, the chemotherapy segment is expected to dominate the Colombia gastric cancer treatment market due to the increasing adoption of Chemotherapy with other treatment methods.
  • On the basis of route of administration, the market is segmented into oral and parenteral. In 2022, the parenteral segment is expected to dominate the Colombia gastric cancer drugs market due to high bioavailability of parenteral dosage form along with that most of the product available in the market for gastric cancer of in parenteral form.
  • On the basis of end user, the market is segmented into speciality clinics, hospitals, research and academic institutes, and others. In 2022, the hospitals segment is expected to dominate the Colombia gastric cancer drugs market as hospitals in Colombia are building comprehensive cancer care centers and are the primary source of healthcare in Colombia.
  • On the basis of distribution channel, the market is segmented into retail pharmacy, hospital pharmacy, and others. In 2022, the hospital pharmacy segment disease segment is expected to dominate the Colombia gastric cancer drugs market due to the fact that the gastric cancer patients generally patients prefer hospitals for better care.

Growing Strategic Activities by Major Market Players to Enhance Awareness for Gastric Cancer to Boost the Market Growth

The Colombia Gastric cancer drugs market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for the period 2020 to 2029.

Competitive Landscape and Colombia Gastric Cancer Drugs market Share Analysis

Colombia gastric cancer drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Colombia gastric cancer drugs market

Some of the major companies which are dealing in the Colombia gastric cancer drugs market are Bayer AG, Novartis AG, Pfizer Inc., Celltrion Healthcare Co.,Ltd., F. Hoffmann-La Roche Ltd, Merck KGaA ,Teva Pharmaceutical Industries Ltd., Sanofi, AstraZeneca, Viatris Inc., Bristol-Myers Squibb Company, Concord Biotech, and GlaxoSmithKline plc. among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contracts and agreements are also initiated by the companies worldwide which are further accelerating the Colombia gastric cancer drugs market growth.

For instance,

  • In April 2018, Celltrion Healthcare announced that they have extended the partnership with pharmaceutical provider Mundipharma to license, market and distribute its Truxima cancer treatment drug in Colombia.
  • In November 2020, Pfizer, Inc. announced that its division named Upjohn is combined with Mylan N.V. and formed a new company named Viatris. This combination of the company's business division with Mylan N.V. has increased its product portfolio, leading to increased demand for its product in the market

Customization Available: Colombia Gastric Cancer Drugs Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 2 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY STAGES, 2020-2029 (USD MILLION)

TABLE 3 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 4 COLOMBIA CHEMOTHERAPY IN GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 5 COLOMBIA TARGETED THERAPY IN GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 6 COLOMBIA MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 7 COLOMBIA MULTIKINASE INHIBITORS IN GASTRIC CANCER DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 8 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 9 COLOMBIA PARENTRAL IN GASTRIC CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 10 COLOMBIA ORAL IN GASTRIC CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 11 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 12 COLOMBIA GASTRIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions